sanjeri / iStockphoto.com
BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
Being part of a team that “discovers, develops, and delivers” transformational medicine is one of the reasons that Paul Golian’s job at Bristol-Myers Squibb (BMS) is so rewarding. Another is meeting patients that have benefited from the drugs he has worked on, something that makes him particularly proud.
As vice president and assistant counsel of IP at BMS, New-York based Golian plays a pivotal role in protecting the company’s new therapies.
“My team and I are laser-focused on protecting BMS’s innovations,” he tells LSIPR. This encompasses patent procurement, freedom to operate counselling, negotiating and managing IP provisions in agreements, and patent enforcement.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
LSIPR 50 2018, Paul Golian, BMS, Bristol-Myers Squibb, innovation, biology